1. Home
  2. INDP vs CERS Comparison

INDP vs CERS Comparison

Compare INDP & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

N/A

Current Price

$3.18

Market Cap

438.4M

Sector

Health Care

ML Signal

N/A

Logo Cerus Corporation

CERS

Cerus Corporation

N/A

Current Price

$1.92

Market Cap

465.5M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
INDP
CERS
Founded
2000
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
438.4M
465.5M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
INDP
CERS
Price
$3.18
$1.92
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $5.13
AVG Volume (30 Days)
211.2K
★ 2.5M
Earning Date
11-13-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.27
EPS
N/A
★ N/A
Revenue
N/A
★ $51,326,000.00
Revenue This Year
N/A
$17.63
Revenue Next Year
N/A
$8.79
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 30.68
52 Week Low
$0.92
$1.59
52 Week High
$5.96
$3.47

Technical Indicators

Market Signals
Indicator
INDP
CERS
Relative Strength Index (RSI) 50.79 39.95
Support Level $2.17 $1.73
Resistance Level $3.71 $2.04
Average True Range (ATR) 0.34 0.20
MACD -0.02 -0.03
Stochastic Oscillator 51.34 5.99

Price Performance

Historical Comparison
INDP
CERS

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About CERS Cerus Corporation

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.

Share on Social Networks: